Physician profile
Stephanie Schultz
NPI 1073236253
$1,131.88
in general payments reported to CMS, 2019-2025
11 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $116 · 2023: $345 · 2024: $518 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $370.31 | 2022-2024 | Caplyta |
| Abbvie INC. | $176.90 | 2022-2024 | |
| Merz North America, INC. | $152.03 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $140.16 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $77.43 | 2024 | Wegovy, Ozempic |
| Alkermes, INC. | $59.42 | 2023-2024 | Vivitrol, Vivitrol |
| Exact Sciences Corporation | $50.68 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $41.26 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $22.55 | 2024 | Farxiga |
| Merck Sharp & Dohme LLC | $22.08 | 2024 | Proquad, Vaxneuvance, Vaxelis |
| Lilly USA, LLC | $19.06 | 2024 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.